Innovative pipeline development strategy
Differentiated R&D for Fast New Drug Success and Profitability
- Pipeline
- Indication
- Route of
Administration
-
Discovery
Preclinical
Phase Ⅰ
Phase Ⅲ
Launch
-
Diabetic Macular Edema
Oral
Phase 2a study (us) began in Oct 2022 / Topline data announced in Feb 2024
-
Wet-AMD(Age-related Macular Degeneration)
Oral
Completed phase 1 study (US) in Jun 2022
-
Ulcerative Colitis
Oral
Phase 2 study IND approval(US) in Jun 2023 / IND approval(Europe) in Dec 2023
-
Immuno-Oncology Combination
Oral
Completed phase 1 study (US) in Jun 2022
-
Psoriasis
Topical
-
Next-Generation Endothelial Dysfunction Blocker
Oral
-
Ulcerative Colitis
Oral
High dose Phase 1b study IND submission in Aug 2023
-
Immuno-Oncology Combination
Oral
High dose Phase 1b study IND submission in Aug 2023
- Pipeline
- Indication
- Route of
Administration
-
Discovery
Preclinical
Phase Ⅰ
Phase Ⅲ
Launch
-
Diabetic Nephropathy
Oral
Phase 2b first patient enrolled in Feb 2023
-
Wet-AMD(Age-related Macular Degeneration)
Oral
Finalized phase 2 CSR in Jan 2022
-
Cancer
Oral
-
Cancer
Oral